Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities Centre, Gopalapuram, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control, IDF Centre for Education, Chennai, India.
Diabetes Technol Ther. 2013 Jan;15(1):39-45. doi: 10.1089/dia.2012.0204. Epub 2012 Nov 14.
This study evaluated the noninvasive, point-of-care diabetes screening device, Scout DS (VeraLight Inc., Albuquerque, NM) (SCOUT), in a native Asian Indian cohort.
SCOUT is a tabletop, skin fluorescence spectrometer that reports a risk score following a 3-4-min noninvasive measurement of a subject's left volar forearm. SCOUT, fasting plasma glucose (FPG), and hemoglobin A(1c) (A1C) were compared for detection of abnormal glucose tolerance (AGT) in a cohort of 256 subjects without previous diagnosis of diabetes or impaired glucose tolerance in Chennai, India. After an overnight fast, a 75-g, 2-h oral glucose tolerance test was administered, and AGT was defined as a plasma glucose value ≥ 140 mg/dL (7.8 mmol/dL). Sensitivity, false-positive rate (FPR), and receiver-operating characteristics area under the curve for AGT detection were computed for SCOUT, FPG, and A1C. Intra-day reproducibility of SCOUT was assessed.
SCOUT, FPG, and A1C (at respective thresholds of 50, 110 mg/dL, and 5.7%) exhibited sensitivities of 87%, 32%, and 86%, respectively, and FPR of 52%, 3%, and 58%, respectively. For the 177 subjects receiving a valid SCOUT Diabetes Score on both measurement attempts, the coefficient of variation was 5.8%, and the Pearson correlation was 0.91. A SCOUT score could be obtained on 91% of subjects after two attempts.
The performance of SCOUT is similar to that of A1C, whereas FPG had a much lower sensitivity. SCOUT is an effective tool for AGT screening in Asian Indians.
本研究评估了非侵入性、即时检测的糖尿病筛查设备 Scout DS（VeraLight Inc.，新墨西哥州阿尔伯克基）（SCOUT）在亚洲本地印度人群中的表现。
SCOUT 是一种台式、皮肤荧光光谱仪，在对受试者左掌心进行 3-4 分钟的无创测量后，报告风险评分。在印度钦奈的 256 名受试者中，无糖尿病或糖耐量受损既往诊断史，比较 SCOUT、空腹血糖（FPG）和血红蛋白 A1c（A1C）对异常葡萄糖耐量（AGT）的检测能力。受试者隔夜禁食后，给予 75g、2 小时口服葡萄糖耐量试验，将血浆葡萄糖值≥140mg/dL（7.8mmol/dL）定义为 AGT。计算 SCOUT、FPG 和 A1C 检测 AGT 的敏感性、假阳性率（FPR）和受试者工作特征曲线下面积。评估 SCOUT 的日内重复性。
SCOUT、FPG 和 A1C（各自的阈值分别为 50、110mg/dL 和 5.7%）的敏感性分别为 87%、32%和 86%，FPR 分别为 52%、3%和 58%。在 177 名接受两次测量均有效 SCOUT 糖尿病评分的受试者中，变异系数为 5.8%，Pearson 相关系数为 0.91。两次尝试后，可获得 91%受试者的 SCOUT 评分。
SCOUT 的性能与 A1C 相似，而 FPG 的敏感性要低得多。SCOUT 是亚洲印度人进行 AGT 筛查的有效工具。
